Heterozygous pathogenic variants in POMC are not responsible for monogenic obesity: Implication for MC4R agonist use
-
Published:2023-07
Issue:7
Volume:25
Page:100857
-
ISSN:1098-3600
-
Container-title:Genetics in Medicine
-
language:en
-
Short-container-title:Genetics in Medicine
Author:
Le Collen LaurianeORCID, Delemer Brigitte, Poitou Christine, Vaxillaire Martine, Toussaint Bénédicte, Dechaume Aurélie, Badreddine Alaa, Boissel Mathilde, Derhourhi Mehdi, Clément Karine, Petit Jean M., Mau-Them Frédéric Tran, Bruel Ange-Line, Thauvin-Robinet Christel, Saveanu Alexandru, Cherifi Blandine Gatta, Le Beyec-Le Bihan Johanne, Froguel Philippe, Bonnefond Amélie
Subject
Genetics (clinical)
Reference40 articles.
1. The genetics of obesity: from discovery to biology;Loos;Nat Rev Genet,2022 2. Genetics of obesity in humans;Farooqi;Endocr Rev,2006 3. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials;Clément;Lancet Diabetes Endocrinol,2020 4. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans;Krude;Nat Genet,1998 5. The neuroendocrine circuitry controlled by POMC, MSH, and AGRP;Biebermann;Handb Exp Pharmacol,2012
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|